Moderna and Merck's mRNA Cancer Vaccine Shows Promise in Melanoma Trials

Moderna and Merck's personalized mRNA cancer vaccine, Intisomeran, has shown significant success in late-stage clinical trials, notably reducing the risk of melanoma recurrence and spread. Positive results have led to a substantial surge in Moderna's stock value.